A Non-Linear Association of High-Density Lipoprotein Cholesterol with All-Cause and Cause-Specific Mortality in Diabetic Patients

References

• Gordon T , Castelli WP , Hjortland MC , et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med . 1977;62(5):707–714. doi:10.1016/0002-9343(77)90874-9 193398
   PubMed Web of Science ®Google Scholar
• Barter P , Gotto AM , LaRosa JC , et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med . 2007;357(13):1301–1310. doi:10.1056/NEJMoa064278 17898099
   PubMed Web of Science ®Google Scholar
• Kaysen GA , Ye X , Raimann JG , et al. Lipid levels are inversely associated with infectious and all-cause mortality: international MONDO study results. J Lipid Res . 2018;59(8):1519–1528. doi:10.1194/jlr.P084277 29895699
   PubMed Web of Science ®Google Scholar
• Okamura T , Hayakawa T , Kadowaki T , et al. The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis . 2006;184(1):143–150. doi:10.1016/j.atherosclerosis.2005.03.042 15913635
   PubMed Web of Science ®Google Scholar
• Kinoshita M , Yokote K , Arai H , et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb . 2018;25(9):846–984. doi:10.5551/jat.GL2017 30135334
   PubMed Web of Science ®Google Scholar
• Arnett DK , Blumenthal RS , Albert MA , et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation . 2019;140(11):e596–e646. doi:10.1161/CIR.0000000000000678 30879355
   PubMed Web of Science ®Google Scholar
• Zewinger S , Speer T , Kleber ME , et al. HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction. J Am Soc Nephrol . 2014;25(5):1073–1082. doi:10.1681/ASN.2013050482 24610925
   PubMed Web of Science ®Google Scholar
• Zhong G-C , Huang S-Q , Peng Y , et al. HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies. Eur J Prev Cardiol . 2020;27(11):2047487320914756. doi:10.1177/2047487320914756
   Web of Science ®Google Scholar
• Hamer M , O’Donovan G , Stamatakis E . High-density lipoprotein cholesterol and mortality: too much of a good thing? Arterioscler Thromb Vasc Biol . 2018;38(3):669–672. doi:10.1161/ATVBAHA.117.310587 29326314
   PubMed Web of Science ®Google Scholar
• Li X , Guan B , Wang Y , et al. Association between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern China. Sci Rep . 2019;9(1):14426. doi:10.1038/s41598-019-50924-4 31594968
   PubMed Web of Science ®Google Scholar
• Sharif S , van der Graaf Y , Nathoe HM , et al. HDL cholesterol as a residual risk factor for vascular events and all-cause mortality in patients with type 2 diabetes. Diabetes Care . 2016;39(8):1424–1430. doi:10.2337/dc16-0155 27222511
   PubMed Web of Science ®Google Scholar
• Keene D , Price C , Shun-Shin MJ , et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ . 2014;349(jul18 2):g4379. doi:10.1136/bmj.g4379 25038074
   PubMed Web of Science ®Google Scholar
• Ford ES , Giles WH , Dietz WH . Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA . 2002;287(3):356–359. doi:10.1001/jama.287.3.356 11790215
   PubMed Web of Science ®Google Scholar
• Palmer MK , Toth PP . Trends in lipids, obesity, metabolic syndrome, and diabetes mellitus in the United States: an NHANES analysis (2003–2004 to 2013–2014). Obesity . 2019;27(2):309–314. doi:10.1002/oby.22370 30677260
   PubMed Web of Science ®Google Scholar
• Friedewald WT , Levy RI , Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem . 1972;18(6):499–502. doi:10.1093/clinchem/18.6.499 4337382
   PubMed Web of Science ®Google Scholar
• James PA , Oparil S , Carter BL , et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA . 2014;311(5):507–520. doi:10.1001/jama.2013.284427 24352797
   PubMed Web of Science ®Google Scholar
• Association AD. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care . 2018;41(Suppl 1):S13–S27. doi:10.2337/dc18-S002 29222373
   PubMed Web of Science ®Google Scholar
• Chen C , Ye Y , Zhang Y , et al. Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study. BMJ . 2019;367:l5584. doi:10.1136/bmj.l5584 31619383
   PubMed Web of Science ®Google Scholar
• Oh IH , Hur JK , Ryoo JH , et al. Very high high-density lipoprotein cholesterol is associated with increased all-cause mortality in South Koreans. Atherosclerosis . 2019;283:43–51. doi:10.1016/j.atherosclerosis.2019.01.035 30776703
   PubMed Web of Science ®Google Scholar
• Bowe B , Xie Y , Xian H , et al. High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. veterans. Clin J Am Soc Nephrol . 2016;11(10):1784–1793. doi:10.2215/CJN.00730116 27515591
   PubMed Web of Science ®Google Scholar
• Madsen CM , Varbo A , Nordestgaard BG . Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J . 2017;38(32):2478–2486. doi:10.1093/eurheartj/ehx163 28419274
   PubMed Web of Science ®Google Scholar
• Navaneethan SD , Schold JD , Walther CP , et al. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol . 2018;12(4):1061–1071.e7. doi:10.1016/j.jacl.2018.03.085 29699917
   PubMed Web of Science ®Google Scholar
• Mazidi M , Mikhailidis DP , Banach M . Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults. Int J Cardiol . 2019;276:242–247. doi:10.1016/j.ijcard.2018.11.095 30473336
   PubMed Web of Science ®Google Scholar
• Verdoia M , Schaffer A , Suryapranata H , et al. Effects of HDL-modifiers on cardiovascular outcomes: a meta-analysis of randomized trials. Nutr Metab Cardiovasc Dis . 2015;25(1):9–23. doi:10.1016/j.numecd.2014.09.003 25439661
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt R . Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis . 2010;208(2):305–316. doi:10.1016/j.atherosclerosis.2009.06.005 19596329
   PubMed Web of Science ®Google Scholar
• Genga KR , Trinder M , Kong HJ , et al. CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis. Sci Rep . 2018;8(1):16764. doi:10.1038/s41598-018-35261-2 30425299
   PubMed Web of Science ®Google Scholar
• Voight BF , Peloso GM , Orho-Melander M , et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet . 2012;380(9841):572–580. doi:10.1016/S0140-6736(12)60312-2 22607825
   PubMed Web of Science ®Google Scholar
• Holmes MV , Ala-Korpela M , Smith GD . Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol . 2017;14(10):577–590. doi:10.1038/nrcardio.2017.78 28569269
   PubMed Web of Science ®Google Scholar
• Sung K-C , Ryu S , Wild SH , et al. An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart . 2015;101(7):553–558. doi:10.1136/heartjnl-2014-306784 25637367
   PubMed Web of Science ®Google Scholar
• Kontush A , Chapman MJ . Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev . 2006;58(3):342–374. doi:10.1124/pr.58.3.1 16968945
   PubMed Web of Science ®Google Scholar